Yukinori Matsuo

List of Publications by Year
in descending order

| 158 papers | 3,913 citations | 147786 31 h-index | 138468 58 g-index |
| 161 all docs | 161 docs citations | 161 times ranked | 3207 citing authors |

#	Article	IF	Citations
1	Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1427-1431.	0.8	646
2	Stereotactic Body Radiotherapy for Oligometastatic Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2008, 72, 398-403.	0.8	202
3	Dose–Volume Metrics Associated With Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, e545-e549.	0.8	176
4	Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival after Stereotactic Body Radiation Therapy for Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 116-125.	1.1	135
5	Survey of Stereotactic Body Radiation Therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. International Journal of Radiation Oncology Biology Physics, 2009, 75, 343-347.	0.8	132
6	Prognostic Factors in Stereotactic Body Radiotherapy for Non–Small-Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1104-1111.	0.8	101
7	Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. European Journal of Cancer, 2014, 50, 2932-2938.	2.8	93
8	Video-Assisted Thoracoscopic Lobectomy Versus Stereotactic Radiotherapy for Stage I Lung Cancer. Annals of Thoracic Surgery, 2015, 99, 1122-1129.	1.3	87
9	Salvage Lung Resection for Non-small Cell Lung Cancer After Stereotactic Body Radiotherapy in Initially Operable Patients. Journal of Thoracic Oncology, 2010, 5, 1999-2002.	1.1	81
10	Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiotherapy and Oncology, 2010, 97, 200-204.	0.6	71
11	Evaluation of mass-like consolidation after stereotactic body radiation therapy for lung tumors. International Journal of Clinical Oncology, 2007, 12, 356-362.	2.2	68
12	Dosimetric comparison of Acuros XB, AAA, and XVMC in stereotactic body radiotherapy for lung cancer. Medical Physics, 2014, 41, 081715.	3.0	64
13	Analysis of Dosimetric Parameters Associated With Acute Gastrointestinal Toxicity and Upper Gastrointestinal Bleeding in Locally Advanced Pancreatic Cancer Patients Treated With Gemcitabine-Based Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, 369-375.	0.8	62
14	Evaluation of dynamic tumour tracking radiotherapy with real-time monitoring for lung tumours using a gimbal mounted linac. Radiotherapy and Oncology, 2014, 112, 360-364.	0.6	62
15	Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. Journal of Radiation Research, 2015, 56, 561-567.	1.6	57
16	Geometrical differences in target volumes between slow CT and 4D CT imaging in stereotactic body radiotherapy for lung tumors in the upper and middle lobe. Medical Physics, 2008, 35, 4142-4148.	3.0	56
17	Current status of stereotactic body radiotherapy for lung cancer. International Journal of Clinical Oncology, 2007, 12, 3-7.	2.2	52
18	Medical Physics, 2013, 40, 091705.	3.0	52

#	Article	IF	Citations
19	Positional Reproducibility of Pancreatic Tumors Under End-Exhalation Breath-Hold Conditions Using a Visual Feedback Technique. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1565-1571.	0.8	50
20	Guidelines for respiratory motion management in radiation therapy. Journal of Radiation Research, 2013, 54, 561-568.	1.6	49
21	Impact of motion velocity on four‐dimensional target volumes: A phantom study. Medical Physics, 2009, 36, 1610-1617.	3.0	48
22	Interinstitutional Variations in Planning for Stereotactic Body Radiation Therapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 68, 416-425.	0.8	47
23	Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1616-1624.	1.1	46
24	Interfraction variation in lung tumor position with abdominal compression during stereotactic body radiotherapy. Medical Physics, 2013, 40, 091718.	3.0	45
25	Intra- and interfractional variations in geometric arrangement between lung tumours and implanted markers. Radiotherapy and Oncology, 2014, 110, 523-528.	0.6	41
26	Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. Radiation Oncology, 2014, 9, 112.	2.7	38
27	Multi‐institutional dose‐segmented dosiomic analysis for predicting radiation pneumonitis after lung stereotactic body radiation therapy. Medical Physics, 2021, 48, 1781-1791.	3.0	37
28	Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 453-456.	1.1	36
29	Stereotactic body radiation therapy (SBRT) for early-stage lung cancer. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2007, 11, 32-35.	1.4	35
30	Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Strahlentherapie Und Onkologie, 2014, 190, 485-490.	2.0	35
31	Comparison of radiomic features in diagnostic CT images with and without contrast enhancement in the delayed phase for NSCLC patients. Physica Medica, 2020, 69, 176-182.	0.7	34
32	Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer with PTV < 100 cc using a continual reassessment method (JCOG0702). Radiotherapy and Oncology, 2015, 116, 276-280.	0.6	33
33	Phase II Study of Radiation Therapy Combined With Weekly Low-Dose Gemcitabine for Locally Advanced, Unresectable Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 115-119.	1.3	32
34	Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1). International Journal of Clinical Oncology, 2017, 22, 849-856.	2.2	31
35	Dose Escalation Improves Outcome in Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Colorectal Cancer. Anticancer Research, 2017, 37, 2709-2713.	1.1	31
36	A scoring system predicting acute radiation dermatitis in patients with head and neck cancer treated with intensity-modulated radiotherapy. Radiation Oncology, 2019, 14, 14.	2.7	30

#	Article	IF	Citations
37	Intrafractional tracking accuracy in infrared marker-based hybrid dynamic tumour-tracking irradiation with a gimballed linac. Radiotherapy and Oncology, 2014, 111, 301-305.	0.6	29
38	Dynamic tumor-tracking radiotherapy with real-time monitoring for liver tumors using a gimbal mounted linac. Radiotherapy and Oncology, 2015, 117, 496-500.	0.6	29
39	Feasibility evaluation of a new irradiation technique: three-dimensional unicursal irradiation with the Vero4DRT (MHI-TM2000). Journal of Radiation Research, 2013, 54, 330-336.	1.6	28
40	Stereotactic Body Radiation Therapy for Patients with Pulmonary Interstitial Change: High Incidence of Fatal Radiation Pneumonitis in a Retrospective Multi-Institutional Study. Cancers, 2018, 10, 257.	3.7	28
41	Clinical Outcomes of Stereotactic Body Radiotherapy for Patients With Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database. Technology in Cancer Research and Treatment, 2018, 17, 153303381878390.	1.9	27
42	Measurement of Interfraction Variations in Position and Size of Target Volumes in Stereotactic Body Radiotherapy for Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 543-548.	0.8	26
43	Incidence and Risk Factors of Symptomatic Radiation Pneumonitis in Non–Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Consolidation Durvalumab. Clinical Lung Cancer, 2021, 22, 401-410.	2.6	26
44	Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a planning protocol. International Journal of Clinical Oncology, 2012, 17, 505-511.	2.2	25
45	Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and 18F-FDG PET. European Journal of Radiology, 2014, 83, 2087-2092.	2.6	25
46	Effect of Audio Coaching on Correlation of Abdominal Displacement With Lung Tumor Motion. International Journal of Radiation Oncology Biology Physics, 2009, 75, 558-563.	0.8	24
47	Application and limitation of radiomics approach to prognostic prediction for lung stereotactic body radiotherapy using breath–hold CT images with random survival forest: A multi–institutional study. Medical Physics, 2020, 47, 4634-4643.	3.0	23
48	Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 619-626.	0.8	22
49	Evaluation of the prevalence of burnout and psychological morbidity among radiation oncologist members of the Kyoto Radiation Oncology Study Group (KROSG). Journal of Radiation Research, 2017, 58, 217-224.	1.6	22
50	Initial characterization, dosimetric benchmark and performance validation of Dynamic Wave Arc. Radiation Oncology, 2016, 11, 63.	2.7	21
51	Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702): Results for the group with PTV â©¾ 100 cc. Radiotherapy and Oncology, 2017, 122, 281-285.	0.6	21
52	Interfractional Reproducibility in Pancreatic Position Based on Four-Dimensional Computed Tomography. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1567-1572.	0.8	20
53	The impact of abdominal compression on outcome in patients treated with stereotactic body radiotherapy for primary lung cancer. Journal of Radiation Research, 2014, 55, 934-939.	1.6	20
54	Quantification of the kV X-ray imaging dose during real-time tumor tracking and from three- and four-dimensional cone-beam computed tomography in lung cancer patients using a Monte Carlo simulation. Journal of Radiation Research, 2018, 59, 173-181.	1.6	18

#	Article	IF	Citations
55	Impact of low skeletal muscle mass on non-lung cancer mortality after stereotactic body radiotherapy for patients with stage I non-small cell lung cancer. Journal of Geriatric Oncology, 2018, 9, 589-593.	1.0	18
56	Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma â€" benchmark for a prospective multi-institutional study. Radiation Oncology, 2013, 8, 113.	2.7	17
57	Recurrence patterns after postoperative radiotherapy for squamous cell carcinoma of the pharynx and larynx. Acta Oto-Laryngologica, 2015, 135, 96-102.	0.9	17
58	A Retrospective Long-term Follow-up Study of Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer From a Single Institution: Incidence of Late Local Recurrence. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1228-1236.	0.8	17
59	Development of a fourâ€axis moving phantom for patientâ€specific QA of surrogate signalâ€based tracking IMRT. Medical Physics, 2016, 43, 6364-6374.	3.0	16
60	Comparative evaluation of respiratory-gated and ungated FDG-PET for target volume definition in radiotherapy treatment planning for pancreatic cancer. Radiotherapy and Oncology, 2016, 120, 217-221.	0.6	16
61	Case Series of 23 Patients Who Developed Fatal Radiation Pneumonitis After Stereotactic Body Radiotherapy for Lung Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381880132.	1.9	16
62	The accuracy of extracted target motion trajectories in four-dimensional cone-beam computed tomography for lung cancer patients. Radiotherapy and Oncology, 2016, 121, 46-51.	0.6	15
63	Stereotactic Body Radiation Therapy for Lung Cancer: Achievements and Perspectives. Japanese Journal of Clinical Oncology, 2010, 40, 846-854.	1.3	14
64	Interfractional dose variations in the stomach and the bowels during breathhold intensity-modulated radiotherapy for pancreatic cancer: Implications for a dose-escalation strategy. Medical Physics, 2013, 40, 021701.	3.0	14
65	Dosimetric evaluation of the Acuros XB algorithm for a 4 MV photon beam in head and neck intensity-modulated radiation therapy. Journal of Applied Clinical Medical Physics, 2015, 16, 52-64.	1.9	14
66	Evaluation of Dynamic Tumor-tracking Intensity-modulated Radiotherapy for Locally Advanced Pancreatic Cancer. Scientific Reports, 2018, 8, 17096.	3.3	14
67	Optimization of the x-ray monitoring angle for creating a correlation model between internal and external respiratory signals. Medical Physics, 2012, 39, 6309-6315.	3.0	13
68	Differences in dose-volumetric data between the analytical anisotropic algorithm and the x-ray voxel Monte Carlo algorithm in stereotactic body radiation therapy for lung cancer. Medical Dosimetry, 2013, 38, 95-99.	0.9	13
69	Target localization errors from fiducial markers implanted around a lung tumor for dynamic tumor tracking. Physica Medica, 2015, 31, 934-941.	0.7	13
70	Multivariate analysis for the estimation of target localization errors in fiducial markerâ€based radiotherapy. Medical Physics, 2016, 43, 1907-1912.	3.0	13
71	Development of a four-dimensional Monte Carlo dose calculation system for real-time tumor-tracking irradiation with a gimbaled X-ray head. Physica Medica, 2017, 35, 59-65.	0.7	13
72	Use of a second-dose calculation algorithm to check dosimetric parameters for the dose distribution of a first-dose calculation algorithm for lung SBRT plans. Physica Medica, 2017, 44, 86-95.	0.7	13

#	Article	IF	Citations
73	Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy. Anticancer Research, 2017, 37, 5161-5167.	1.1	13
74	Impact of multileaf collimator width on intraprostatic dose painting plans for dominant intraprostatic lesion of prostate cancer. Journal of Applied Clinical Medical Physics, 2010, 11, 144-154.	1.9	12
75	Dosimetric evaluation of the impacts of different heterogeneity correction algorithms on target doses in stereotactic body radiation therapy for lung tumors. Journal of Radiation Research, 2012, 53, 777-784.	1.6	12
76	Interfractional Dose Variations in Intensity-Modulated Radiotherapy With Breath-Hold for Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1619-1626.	0.8	12
77	Assessment of treatment response after lung stereotactic body radiotherapy using diffusion weighted magnetic resonance imaging and positron emission tomography: A pilot study. European Journal of Radiology, 2017, 92, 58-63.	2.6	12
78	Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy. Journal of Radiation Research, 2018, 59, 50-57.	1.6	12
79	New algorithm to simulate organ movement and deformation for four-dimensional dose calculation based on a three-dimensional CT and fluoroscopy of the thorax. Medical Physics, 2009, 36, 4328-4339.	3.0	11
80	The gimbaled-head radiotherapy system: Rise and downfall of a dedicated system for dynamic tumor tracking with real-time monitoring and dynamic WaveArc. Radiotherapy and Oncology, 2020, 153, 311-318.	0.6	11
81	Hyperfractionated Irradiation with 3 Cycles of Induction Chemotherapy in Stage IIIA-N2 Lung Cancer. World Journal of Surgery, 2012, 36, 2858-2864.	1.6	10
82	Differences in the dose-volume metrics with heterogeneity correction status and its influence on local control in stereotactic body radiation therapy for lung cancer. Journal of Radiation Research, 2013, 54, 337-343.	1.6	10
83	A multi-centre analysis of treatment procedures and error components in dynamic tumour tracking radiotherapy. Radiotherapy and Oncology, 2015, 115, 412-418.	0.6	10
84	Influence of the correlation modeling period on the prediction accuracy of infrared marker-based dynamic tumor tracking using a gimbaled X-ray head. Physica Medica, 2015, 31, 204-209.	0.7	10
85	Safety and effectiveness of stereotactic body radiotherapy for a clinically diagnosed primary stage I lung cancer without pathological confirmation. International Journal of Clinical Oncology, 2014, 19, 814-821.	2.2	9
86	Baseline correction of a correlation model for improving the prediction accuracy of infrared marker-based dynamic tumor tracking. Journal of Applied Clinical Medical Physics, 2015, 16, 14-22.	1.9	9
87	Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702). Japanese Journal of Clinical Oncology, 2018, 48, 1076-1082.	1.3	9
88	A Systematic Literature Review on Salvage Radiotherapy for Local or Regional Recurrence After Previous Stereotactic Body Radiotherapy for Lung Cancer. Technology in Cancer Research and Treatment, 2018, 17, 153303381879863.	1.9	9
89	Impact of sampling interval in training data acquisition on intrafractional predictive accuracy of indirect dynamic tumor-tracking radiotherapy. Medical Physics, 2017, 44, 3899-3908.	3.0	7
90	Optimization of a newly defined target volume in fiducial marker-based dynamic tumor-tracking radiotherapy. Physics and Imaging in Radiation Oncology, 2017, 4, 1-5.	2.9	7

#	Article	IF	Citations
91	Pilot Study of the Safety and Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumors. Clinical Lung Cancer, 2018, 19, e287-e296.	2.6	7
92	Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. International Journal of Clinical Oncology, 2020, 25, 274-281.	2.2	7
93	Investigation of 4D dose in volumetric modulated arc therapy-based stereotactic body radiation therapy: does fractional dose or number of arcs matter?. Journal of Radiation Research, 2020, 61, 325-334.	1.6	7
94	Appropriate margin for planning target volume for breast radiotherapy during deep inspiration breath-hold by variance component analysis. Radiation Oncology, 2021, 16, 49.	2.7	7
95	Evaluation of 4D dose to a moving target with Monte Carlo dose calculation in stereotactic body radiotherapy for lung cancer. Radiological Physics and Technology, 2013, 6, 233-240.	1.9	6
96	Dosimetric comparison of lung stereotactic body radiotherapy treatment plans using averaged computed tomography and end-exhalation computed tomography images: Evaluation of the effect of different dose-calculation algorithms and prescription methods. Medical Dosimetry, 2016, 41, 305-309.	0.9	6
97	Validation of the clinical applicability of knowledge‐based planning models in single‐isocenter volumetric‐modulated arc therapy for multiple brain metastases. Journal of Applied Clinical Medical Physics, 2020, 21, 141-150.	1.9	6
98	Dosimetric investigation of breath-hold intensity-modulated radiotherapy for pancreatic cancer. Medical Physics, 2011, 39, 48-54.	3.0	5
99	Experimental validation of heterogeneity-corrected dose-volume prescription on respiratory-averaged CT images in stereotactic body radiotherapy for moving tumors. Medical Dosimetry, 2012, 37, 20-25.	0.9	5
100	Long-term outcomes of intensity-modulated radiotherapy following extra-pleural pneumonectomy for malignant pleural mesothelioma. Acta Oncológica, 2017, 56, 957-962.	1.8	5
101	Salvage Pulmonary Metastasectomy for Local Relapse After Stereotactic Body Radiotherapy. Annals of Thoracic Surgery, 2018, 105, e165-e168.	1.3	5
102	Surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer: review of meta-analyses. Journal of Thoracic Disease, 2019, 11, S1646-S1652.	1.4	5
103	Dosiomic feature comparison between dose-calculation algorithms used for lung stereotactic body radiation therapy. Radiological Physics and Technology, 2022, 15, 63-71.	1.9	5
104	Technical Note: Introduction of variance component analysis to setup error analysis in radiotherapy. Medical Physics, 2016, 43, 5195-5198.	3.0	4
105	Salvage video-assisted thoracoscopic lobectomy for isolated local relapse after stereotactic body radiotherapy for early stage non-small cell lung cancer: technical aspects and perioperative management. Journal of Visualized Surgery, 2017, 3, 86-86.	0.2	4
106	Development and validation of a prognostic model for non-lung cancer death in elderly patients treated with stereotactic body radiotherapy for non-small cell lung cancer. Journal of Radiation Research, 2021, , .	1.6	4
107	Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors. Radiotherapy and Oncology, 2022, 172, 18-22.	0.6	4
108	Radiation therapy for tumor thrombus in the portal vein or inferior vena cava in unresectable hepatocellular carcinoma. Acta Hepatologica Japonica, 2012, 53, 486-493.	0.1	3

#	Article	IF	Citations
109	Dosimetric impact of gold markers implanted closely to lung tumors: a Monte Carlo simulation. Journal of Applied Clinical Medical Physics, 2014, 15, 71-79.	1.9	3
110	Tumour volume comparison between 16-row multi-detector computed tomography and 320-row area-detector computed tomography in patients with small lung tumours treated with stereotactic body radiotherapy: Effect of respiratory motion. European Journal of Radiology, 2019, 117, 120-125.	2.6	3
111	Sarcopenia is a potential factor for optimized treatment selection for elderly patients with early stage non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, S443-S445.	1.4	3
112	Independent calculation–based verification of volumetric–modulated arc therapy–stereotactic body radiotherapy plans for lung cancer. Journal of Applied Clinical Medical Physics, 2020, 21, 135-143.	1.9	3
113	TH-D-210A-09: Correlation Between Abdominal Organ Motion and An External Marker Toward Respiratory-Gated Intensity-Modulated Radiation Therapy for Pancreatic Carcinoma. Medical Physics, 2009, 36, 2820-2820.	3.0	3
114	Impact of Local Recurrence on Cause-Specific Death After Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Dynamic Prediction Using Landmark Model. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1135-1143.	0.8	3
115	Effects of interportal error on dose distribution in patients undergoing breath–holding intensity–modulated radiotherapy for pancreatic cancer: evaluation of a new treatment planning method. Journal of Applied Clinical Medical Physics, 2013, 14, 43-51.	1.9	2
116	A promising result of locoregional tumor control with biologically adaptive radiotherapy in patients with locally advanced non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S111-S113.	2.8	2
117	Stereotactic body radiotherapy as an alternative to metastasectomy for pulmonary oligometastasis. Journal of Thoracic Disease, 2019, 11, S1420-S1422.	1.4	2
118	Efficacy of local salvage therapy for recurrent uterine cervical cancer after definitive radiotherapy. International Journal of Clinical Oncology, 2021, 26, 1968-1976.	2.2	2
119	Impact of pre-treatment C-reactive protein level and skeletal muscle mass on outcomes after stereotactic body radiotherapy for T1N0M0 non-small cell lung cancer: a supplementary analysis of the Japan Clinical Oncology Group study JCOG0403. Journal of Radiation Research, 2021, 62, 901-909.	1.6	2
120	SU-E-J-142: Gafchromic Film Dosimetry in Fluoroscopy for Dynamic Tumor Tracking Irradiation of the Lung Using XR-SP2 Model - A Phantom Study -. Medical Physics, 2012, 39, 3685-3685.	3.0	2
121	Single Nucleotide Polymorphisms of Inflammation-Related Genes As Predictive Risk Factors of Radiation Pneumonitis after Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e699-e700.	0.8	1
122	Updated long-term outcomes of salvage surgery after stereotactic body radiotherapy for early-stage non-small-cell lung cancer. Interactive Cardiovascular and Thoracic Surgery, 2020, 31, 892-894.	1.1	1
123	Dynamic tumor-tracking stereotactic body radiation therapy for a solitary tumor in a transplanted organ: two case reports. International Cancer Conference Journal, 2020, 9, 221-226.	0.5	1
124	Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer. In Vivo, 2020, 34, 897-902.	1.3	1
125	Transurethral coil embolization for the management of ureteroarterial fistula: a case report. Acta Urologica Japonica, 2004, 50, 53-5.	0.1	1
126	Development of AI-driven prediction models to realize real-time tumor tracking during radiotherapy. Radiation Oncology, 2022, 17, 42.	2.7	1

#	Article	IF	Citations
127	Lack of an association between marital status and survival in patients receiving stereotactic body radiotherapy for early-stage non-small-cell lung cancer. PLoS ONE, 2022, 17, e0269463.	2.5	1
128	Usefulness of pro-gastrin-releasing peptide as a predictor of the incidence of brain metastasis and effect of prophylactic cranial irradiation in patients with limited-stage small-cell lung cancer. Journal of Radiation Research, 0, , .	1.6	1
129	E14-02: Stereotactic body radiotherapy for lung cancer. Journal of Thoracic Oncology, 2007, 2, S264-S265.	1.1	0
130	Target displacement evaluation for fluoroscopic and four-dimensional cone-beam computed tomography. Radiotherapy and Oncology, 2016, 119, S148.	0.6	0
131	EP-1201: Impact of low skeletal muscle mass on survival after SBRT for non-small cell lung cancer. Radiotherapy and Oncology, 2016, 119, S570.	0.6	0
132	EP-1760: Correlation and directional stability of principal component of respiratory motion in the lung. Radiotherapy and Oncology, 2016, 119, S824-S825.	0.6	0
133	PO-0807: 3D and 4D dose calculations for tumour-tracking irradiation of lung/liver tumours using gimbaled linac. Radiotherapy and Oncology, 2016, 119, S381.	0.6	0
134	P2.05-050 Impact of Inflammation and Sarcopenia on Outcomes after Stereotactic Body Radiotherapy for T1N0M0 Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1062-S1063.	1.1	0
135	EP-1224: Therapeutic effects of accelerated hyperfractionation and conventional fractionation CRT on NSCLC. Radiotherapy and Oncology, 2017, 123, S660-S661.	0.6	0
136	MS 24.04 Possibility of Radiotherapy for GGO-Containing Tumors. Journal of Thoracic Oncology, 2017, 12, S1722-S1723.	1.1	0
137	P2.05-002 A Pilot Study on the Safety and the Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumor. Journal of Thoracic Oncology, 2017, 12, S2403-S2404.	1.1	0
138	Optimization of training periods for the estimation model of three-dimensional target positions using an external respiratory surrogate. Radiation Oncology, 2018, 13, 73.	2.7	0
139	P1.16-25 A Propensity Score Model for Appropriate Treatment Selection (Sublobar Resection vs. SBRT) In Patients With cStage I NSCLC. Journal of Thoracic Oncology, 2018, 13, S636-S637.	1.1	0
140	EP-1829 Clinical validation of knowledge-based planning for multiple brain metastases. Radiotherapy and Oncology, 2019, 133, S992-S993.	0.6	0
141	Prognosis after Local Recurrence or Metastases in Medically Operable Stage I Non-Small Cell Lung Cancer Patients Treated By Stereotactic Body Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2019, 105, E525-E526.	0.8	0
142	Safe Delivery of Postoperative Radiotherapy for Thymic Carcinoma Located on the Outflow Graft of a Left Ventricular Assist Device. JTO Clinical and Research Reports, 2021, 2, 100101.	1.1	0
143	TUâ€EEâ€A3â€06: Impact of Respiratory Velocity On Target Volume Using 4DCT. Medical Physics, 2008, 35, 2913-2913.	3.0	0
144	Stereotactic Body Radiotherapy for the Lung. , 2011, , 267-277.		0

#	Article	IF	Citations
145	SU-E-J-147: Effect of Audio Instruction on the Tracking Accuracy for a Four- Dimensional Image-Guided Radiotherapy System, MHI-TM2000 (VERO). Medical Physics, 2011, 38, 3476-3477.	3.0	0
146	Organ preservation treatment for locally advanced laryngeal cancer at the Comprehensive Cancer Center of Kyoto University. Japanese Journal of Head and Neck Cancer, 2012, 38, 447-453.	0.1	0
147	Definitive radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer: A retrospective analysis.. Journal of Clinical Oncology, 2012, 30, 366-366.	1.6	0
148	SUâ€Câ€BRAâ€04: Determination of the Optimal Xâ€Ray Monitoring Angle for Creating a Correlation Model in Dynamic Tumor Tracking Irradiation with Vero4DRT(MHIâ€TM2000). Medical Physics, 2012, 39, 3603-3603.	3.0	0
149	Development of four-dimensional Monte Carlo dose calculation system for dynamic tumor-tracking irradiation with a gimbaled X-ray head. IFMBE Proceedings, 2013, , 1791-1794.	0.3	0
150	A case of severe thrombocytopenia following multimodal treatment for malignant pleural mesothelioma. The Journal of the Japanese Association for Chest Surgery, 2014, 28, 777-782.	0.0	0
151	Stereotactic Body Radiotherapy for Early Stage Lung Cancer. Japanese Journal of Lung Cancer, 2014, 54, 821-824.	0.1	0
152	SU-E-T-351: Verification of Monitor Unit Calculation for Lung Stereotactic Body Radiation Therapy Using a Secondary Independent Planning System. Medical Physics, 2014, 41, 305-305.	3.0	0
153	Development and Clinical Application of Vero4DRT System. , 2015, , 205-215.		0
154	Title is missing!. Japanese Journal of Lung Cancer, 2016, 56, 988-990.	0.1	0
155	Updates on Radiotherapy for Lung Cancer. Japanese Journal of Lung Cancer, 2019, 59, 1104-1106.	0.1	0
156	Symptomatic radiation pneumonitis after stereotactic body radiotherapy for multiple pulmonary oligometastases or synchronous primary lung cancer. Advances in Radiation Oncology, 2022, , 100911.	1.2	0
157	Applying Artificial Neural Networks to Develop a Decision Support Tool for Tisâ€"4N0M0 Nonâ€"Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy. JCO Clinical Cancer Informatics, 2022, , .	2.1	0
158	Propensity score-based analysis of stereotactic body radiotherapy, lobectomy and sublobar resection for stage I non-small cell lung cancer. Journal of Radiation Research, 0, , .	1.6	0